OT- FMTI I bought a little. The neutraceutical business justifies the market cap by itself. I was a bit disappointed by the fluff PR promising subset analysis. Like anyone thought they couldn't find a subgroup that showed better numbers. BTW, Drbio that message was funny. Regards, Bob